What's new

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 6, Status: Authorised

May 16, 2025 - 13:14
 0
Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 6, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Flucelvax, influenza v...

Next Article

Björn Borg: apparel and shoes drive turnover in first quarter

Related Posts

Veterinary medicines European public assessment report (EPAR): Fluralaner Intervet, fluralaner, Status: Opinion

Veterinary medicines European public assessment report ...

May 16, 2025  0

Summary of opinion: NexGard Combo, 15/05/2025 Positive

Summary of opinion: NexGard Combo, 15/05/2025 Positive

May 16, 2025  0

CVMP Interested Parties’ meeting May 2025, European Medicines Agency, Amsterdam, the Netherlands, from 14 May 2024, 17:00 (CEST) to 14 May 2024, 19:00 (CEST)

CVMP Interested Parties’ meeting May 2025, European Med...

May 5, 2025  0